Cadence Pharmaceuticals (CADX) Reports a Q3 Loss
More News related to CADX
- Oppenheimer Downgrades Cadence Pharmaceuticals (CADX) to Perform
- Cadence Pharma (CADX) Dec volatility at 63, Feb at 111 into FDA goal date
- FDA Extends Cadence Pharmaceuticals (CADX) PDUFA Date by Three Months
- Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
- Cadence Pharmaceuticals (CADX) Up Ahead of Tomorrow's PDUFA Date
More News related to Earnings
- After-Hours Movers 11/24: QADI, JCG, ASYS Higher; DRAM, CWTR Lower
- Trading Radar for 11/25: Deere & Co. (DE), Tiffany & Co. (TIF), Conn's (CONN) Report
- Afternoon ETF Check: SMH Up; XLF, TAN, EWJ Down
- Unusual 11 Mid-Day Movers 11/24: IWA, DRAM, ABG, TIXC Higher; WH, WMG, ABIO, NYNY Lower
- Notable Analyst Rating Changes 11/24: ABG, PRU, RS, AYI, AMLN, TLAB Upgraded; DELL, CIEN, UNP, ALV Downgraded
Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) reports a Q3 loss of $0.23, 4 cents better than the analyst estimate of ($0.27).
Related Categories
EarningsStocks Mentioned
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
